Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease

[1]  D. Mansuy,et al.  Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. , 2012, Chemical research in toxicology.

[2]  T. Andersson,et al.  In Vitro Evaluation of Potential Drug-Drug Interactions with Ticagrelor: Cytochrome P450 Reaction Phenotyping, Inhibition, Induction, and Differential Kinetics , 2011, Drug Metabolism and Disposition.

[3]  S. Oliver,et al.  Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects , 2010, Drug Metabolism and Disposition.

[4]  Henrik Sillén,et al.  Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  R. Teng,et al.  Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. , 2010, British journal of clinical pharmacology.

[6]  J. Eikelboom,et al.  Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study , 2010, Circulation.

[7]  R. Teng,et al.  Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects , 2010, European Journal of Clinical Pharmacology.

[8]  S. Husted,et al.  Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist , 2009, Cardiovascular therapeutics.

[9]  Mark J. Antonino,et al.  Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study , 2009, Circulation.

[10]  F. Giordanetto,et al.  Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation , 2009, Journal of thrombosis and haemostasis : JTH.

[11]  W. Ahmad.  Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. , 2009 .

[12]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[13]  C. Cannon,et al.  Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. , 2007, Journal of the American College of Cardiology.

[14]  C. Cannon,et al.  Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. , 2007, Journal of the American College of Cardiology.

[15]  P. Leeson,et al.  From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. , 2007, Bioorganic & medicinal chemistry letters.

[16]  S. Nesbitt,et al.  Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk , 2007, Blood pressure.

[17]  P. Sandset,et al.  Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. , 2006, European heart journal.

[18]  R. G. Humphries,et al.  Preclinical and Clinical Studies with Selective Reversible Direct P2Y12 Antagonists , 2005, Seminars in thrombosis and hemostasis.

[19]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[20]  M. Maftouh,et al.  Structure and stereochemistry of the active metabolite of clopidogrel. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[21]  N. Toma.  Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of Ticagrelor versus Clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET study. , 2010, Maedica.

[22]  S. Steinhubl,et al.  Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. , 2008, Thrombosis research.